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ABSTRACT
Objective To quantify the impact of a practical,
hospital-based nurse-coordinated prevention programme
on cardiovascular risk, integrated into the routine clinical
care of patients discharged after an acute coronary
syndrome, as compared with usual care only.
Design RESPONSE (Randomised Evaluation of
Secondary Prevention by Outpatient Nurse SpEcialists)
was a randomised clinical trial.
Setting Multicentre trial in secondary and tertiary
healthcare settings.
Participants 754 patients admitted for acute coronary
syndrome.
Intervention A nurse-coordinated prevention
programme, consisting of four outpatient nurse clinic
visits, focusing on healthy lifestyles, biometric risk factors
and medication adherence, in addition to usual care.
Main outcome measures The main outcome was
10-year cardiovascular mortality risk as estimated by
Systematic Coronary Risk Evaluation at 12 months follow-
up. Secondary outcomes included Framingham Coronary
Risk Score at 12 months, in addition to changes in
individual risk factors. Risk factor control was classified as
‘poor’ if 0 to 3 factors were on target, ‘fair’ if 4 to 6 factors
were on target, and ‘good’ if 7 to 9 were on target.
Results The mean Systematic Coronary Risk Evaluation at
12 months was 4.4 per cent (SD 4.5) in the intervention
group and 5.4 per cent (SD 6.2) in the control group
(p=0.021), representing a 17.4% relative risk reduction.
At 12 months, risk factor control classified as ‘good’ was
achieved in 35% of patients in the intervention group
compared with 25% in the control group (p=0.003).
Attendance to the nurse-coordinated prevention
programme was 92%. In the intervention group, 86
rehospitalisations were observed against 132 in the control
group (relative risk reduction 34.8%, p=0.023).
Conclusions The nurse-coordinated hospital-based
prevention programme in addition to usual care is a
practical, yet effective method for reduction of
cardiovascular risk in patients with coronary disease.
Our data suggest that the counselling component of the
programme may lead to a reduction in hospital
readmissions.
Trial Registration trialregister.nl Identifier
TC1290.
INTRODUCTION
Patients with established coronary artery disease
(CAD) are at high risk of recurrent coronary events
and mortality. Effective secondary prevention can
reduce this risk, and comprehensive guidelines for
the long-term management of patients with CAD
have been issued by the American Heart
Association/American College of Cardiology,1 and
the European Society of Cardiology.2
At present, a considerable gap exists between
these guidelines and their implementation in clin-
ical practice.3 Nurse-coordinated prevention pro-
grammes may contribute to better achievement
of preventive targets. Previous trials evaluating
such initiatives have been performed in primary
care, or have included complex multidisciplinary
interventions.4–6 We designed the Randomised
Evaluation of Secondary Prevention by Outpatient
Nurse SpEcialists (RESPONSE) trial to quantify
the impact of a practical, hospital-based nurse-
coordinated prevention programme integrated into
the routine clinical care of patients who have sus-
tained an acute coronary syndrome (ACS).
METHODS
Design
RESPONSE is a multicentre, randomised clinical
trial that was conducted in 11 centres in The
Netherlands. Detailed study methods have been
published elsewhere and are summarised here.7
The protocol was approved by the institutional
committees on human research of all recruiting
hospitals.
Trial participants
Patients aged 18–80 years were eligible if they had
been diagnosed with an ACS (ST segment elevation
myocardial infarction, non-ST segment elevation
myocardial infarction or unstable angina pectoris),
within 8 weeks prior to entry into the study.
Patients were ineligible if they met any of the fol-
lowing exclusion criteria: visits to the nurse-
coordinated prevention programmes not feasible;
not available for follow-up; surgery, percutaneous
coronary intervention or other interventions
expected within 8 weeks after inclusion; limited life
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expectancy (≤2 years); previously enrolled in the nurse-
coordinated prevention programme; New York Heart
Association class III or class IV heart failure.
Recruitment and randomisation
Written informed consent was obtained during or shortly after
hospitalisation. Patients were subsequently randomised to either
the nurse-coordinated prevention programme in addition to
usual care (intervention group) or usual care alone (control
group). The online randomisation protocol consisted of a pregen-
erated block-stratified randomisation protocol (http://www.
responsestudie.nl). Study personnel entered patient’s initials,
date of birth and gender, and participating individuals were
assigned a study identification number along with their allocation
to either the intervention group or control group.7 All patients
were informed about the subject of the study, that is, secondary
prevention of coronary disease. However, in order to reduce a
potential Hawthorne-effect,8 9 we did not disclose the fact that
patients were randomised to the nurse-coordinated prevention
programme or usual care only.7 At the end of the trial, all infor-
mation about the actual randomisation was provided to all
patients. The institutional committees on human research expli-
citly approved this process of providing limited trial information
to patients. The randomly assigned treatment of patients was not
disclosed to treating cardiologists or general practitioners.
Usual care included outpatient clinic visits to treating cardiol-
ogists and other relevant specialists. This included referral to
cardiovascular rehabilitation according to the national guidelines
on cardiovascular rehabilitation.10 In short, cardiovascular
rehabilitation typically consisted of a 12 week programme of
evaluation of physical, psychological and social functioning, of
providing education, physical exercise, and interventions to
improve physical and social functioning and to improve cardio-
vascular risk factors and/or risk behaviour.10 Cardiologists were
encouraged, in all patients, to adhere to current national and
international guidelines for secondary prevention of cardiovas-
cular disease.
Nurse-coordinated prevention programme
The programme included four outpatient clinic visits to a car-
diovascular nurse during the first 6 months after inclusion: at
weeks 2, 7, 12 and 17 after baseline. The nurse-coordinated
prevention programme followed a protocol based on national
and international guidelines, focusing on (1) healthy lifestyles,
(2) biometric risk factors and (3) medication adherence.1 2 11
The nine targets for the nurse-coordinated prevention pro-
gramme are presented in box 1.
During each visit, smoking status, dietary status, level of phys-
ical exercise, weight, waist circumference, blood pressure, total
cholesterol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol, triglycerides, glucose and
HbA1c were reviewed. Nurses provided general lifestyle advice,
including dietary advice. Nurses provided specific educational
material and individual counselling to achieve smoking cessation,
adequate physical exercise and healthy weight/fat distribution. In
collaboration with the responsible specialist, treatment of blood
pressure and lipid levels was adjusted to achieve the target levels
described in box 1. This included titration of medication by the
nurse or referral to other health professionals as needed. Patients
with suspected, undiagnosed diabetes or diabetes with inad-
equate glucometabolic control were referred to their treating
physician. Adherence to prescribed medication was encouraged
at each visit, including antithrombotic therapy and a statin. If dis-
continued, reasons for discontinuation were documented, and if
possible the therapy was restarted. Between 6 months (end of the
programme) and 12 months follow-up, there were no visits to
the nurse-coordinated prevention programme.
Nurses contributing to the prevention programme were regis-
tered nurses with a 4-year bachelor’s degree and experience in
the care of cardiac patients (n=15 in 11 centers). They were
selected by the local investigators and received at least one day
of central training in cardiovascular risk management and 1 day
of local individual training in using the study protocol in add-
ition to investigators meetings. All nurses were given a 3-day
course in motivational interviewing at the Department of
Medical Psychology, Academic Medical Center in Amsterdam,
the Netherlands. To assess their ability to deliver the interven-
tion, individual nurses were observed on at least two separate
occasions by study personnel. Video recordings were made of
the nurses’ consultations (with patients’ permission) that were
evaluated by a medical psychologist, who gave feedback to indi-
vidual nurses.
Follow-up and data collection
We collected data at baseline, and at 6 months and 12 months
follow-up. We recorded gender, educational status, work status,
Box 1 Targets for nurse-coordinated prevention
programme11
Lifestyle and biometric targets
Smoking
1. Not smoking
Anthropometry
2. Body mass index <25 kg/m2
3. Waist circumference: for women ≤80 cm, for men ≤94 cm
Blood pressure
4. Systolic blood pressure <140 mm Hg
Blood cholesterol
5. LDL cholesterol concentration ≤2.5 mmol/L
Physical activity
6. ≥30 min of moderate intensity physical activity 5 times a
week
Diet
7. Vegetable consumption ≥200 grams daily
8. Fruit consumption ≥2 pieces daily
9. Alcohol consumption: for women ≤2 units per day, for men
≤3 units per day
Medication adherence
Secondary cardiovascular preventive drug management
Preventive cardiovascular medications are prescribed as
clinically indicated by responsible specialist or general
practitioner, at doses used in usual care for all patients with
coronary heart disease.
▸ Antiplatelet drugs
▸ B-blockers
▸ ACE inhibitors or angiotensin-II receptor blockers
▸ Lipid-lowering drugs (statins)
▸ Diuretics
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civil status, ethnicity, stress status, cardiovascular history,
smoking status prior to index event, dietary status, levels of
physical exercise, medication, weight, height, waist circumfer-
ence and blood pressure. Blood pressure was measured using a
validated automated sphygmomanometer. Blood samples were
analysed by the local laboratories for the measurements of total
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,
glucose and HbA1c. Patients were instructed to observe a period
of 8 h of fasting prior to blood sampling. We recorded data on
all hospital readmissions in 12 months follow-up, including
visits to the cardiology emergency room and visits to the out-
patient clinic of treating cardiologists. All data at baseline,
6 months and 12 months were collected by independent
research personnel not involved in the execution of the nurse-
coordinated prevention programme.
Outcomes
The impact of the intervention was quantified by the proportion
of risk factors on target and by changes in individual risk
factors. To estimate the overall impact on cardiovascular risk,
we used Systematic Coronary Risk Evaluation (SCORE) as an
integrated measure. SCORE estimates the 10 years risk (per
cent) of cardiovascular death based on age, gender, total choles-
terol, systolic blood pressure and smoking status. (The original
trial protocol specifies the Copenhagen risk score as the primary
outcome, which was replaced by SCORE after the Copenhagen
investigators refused to share the algorithm). For all SCORE cal-
culations, we used age at baseline. We did not correct for the
fact that SCORE was developed in populations without previous
cardiovascular events. The primary outcome of the study was
SCORE at 12 months follow-up, that is, at least 6 months after
the last visit to the nurse, in order to include potential late loss
of treatment effect.12
Secondary outcomes included Framingham Coronary Risk
Score (FCRS) at 12 months,13 in addition to changes in individual
risk factors. All of the above risk indicators at 6 months were ana-
lysed as secondary outcomes. The control of risk factors was classi-
fied as ‘poor’ if 0 to 3 factors were on target, ‘fair’ if 4 to 6 factors
were on target, and ‘good’ if 7 to 9 were on target. Patients quali-
fied for a diagnosis of diabetes mellitus if a minimum two mea-
surements of fasting glucose were >7.0 mmol/L or if one
measurement was >11.0 mmol/L regardless of fasting status, or if
1 HbA1c measurement was >6.5%.
Cumulative numbers of hospital readmissions in 12 months
were classified according to diagnosis by treating cardiologists:
readmission for ACS, other cardiac readmissions (chest pain no
ACS, atrial fibrillation, congestive heart failure and cerebrovas-
cular accident) and elective readmissions.
Statistical methods
The primary outcome (SCORE) was compared between the two
groups using a student two-sample t test. For secondary outcomes,
Figure 1 Trial profile.
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means, SD and 95%-confidence intervals (95% CI) were used
to describe continuous variables; frequencies and percentages
were used to describe categorical variables. Comparisons between
groups were summarised as proportion (percentage) mean change
(SD) and number, and independent samples t-tests, χ2 or Fisher’s
exact tests, Yates-Cochran and McNemar tests were applied. We
used SPSS statistics V.18 for all statistical analyses.
With 754 patients in two groups, the study has more than
80% power to detect a difference of 1 point in SCORE function
at 12 months between the two treatment groups, assuming a SD
of 4.5 points.
RESULTS
Figure 1 presents the trial profile. Between June 2006 and July
2009 1666 patients were screened for study enrolment, whereof
1243 met eligibility criteria, and 754 provided consent and
were randomised. In the intervention group, nine patients did
not receive the intervention as randomised, and five patients did
not complete follow-up (three died and two had early discon-
tinuation of intervention). In the control group, 12 patients
were excluded from the study and 18 patients did not complete
follow-up (10 died, 1 lost to follow-up, 7 did not complete
follow-up). Of 710 patients attending 12 months follow-up,
14 patients had incomplete outcome data and 696 patients
(92%) were included in the primary outcome analysis. The
mean number of visits to the nurse-coordinated prevention pro-
gramme was 3.8, and 335/366 (92%) of patients attended the
maximum of all four visits.
Table 1 presents baseline patient characteristics. Patients had a
mean age of 58 years and 80% were men. The majority of
patients had no previous vascular history (73%). The index
event was ST elevation myocardial infarction in 49%, a non-ST
elevation myocardial infarction in 33% and unstable angina pec-
toris in 18%. Coronary revascularisation after the index event
was performed in 79% of patients.
Table 2 presents the proportions of patients with risk factors
on target. At 12 months, more patients in the intervention group
versus the control group were on target for systolic
blood pressure (264 (75%) vs 211 (61%), p<0.001), LDL chol-
esterol (263 (74%) vs 222 (64%), p=0.007), physical activity
(239 (66%) vs 192 (52%), p<0.001), vegetable consumption
(286 (80%) vs 244 (70%), p=0.02) and fruit consumption
(332 (93%) vs 292 (84%) p<0.001). The prevalence of smoking
significantly decreased in both groups, without any difference at
12 months between the two groups (83 (23%) vs 85 (25%),
p=0.72). There was no difference between intervention and
Table 1 Patient characteristics by treatment group
No. (%) of Patients*
Nurse-coordinated prevention
programme Usual care
(N=366) (N=367)
Age (years), mean (SD) 57.5 (9.9) 57.8 (10.4)
Female, n (%) 73 (20%) 74 (20%)
Diagnostic category at index event
STEMI, n (%) 181 (50%) 174 (48%)
NSTEMI, n (%) 120 (33%) 120 (33%)
Unstable angina pectoris, n (%) 55 (17%) 73 (19%)
Therapeutic intervention for index event
No revascularisation, n (%) 71 (19%) 79 (22%)
Percutaneous coronary intervention, n (%) 282 (78%) 271 (75%)
Coronary artery bypass surgery, n (%) 20 (6%) 22 (6%)
Previous vascular disease (prior to index event)
Myocardial infarction, n (%) 60 (16%) 65 (18%)
Percutaneous coronary intervention, n (%) 46 (13%) 55 (15%)
Coronary artery bypass surgery, n (%) 19 (5%) 19 (5%)
Stroke, n (%) 14 (4%) 10 (3%)
Peripheral artery disease, n (%) 20 (6%) 23 (6%)
Congestive heart failure, n (%) 3 (1%) 3 (1%)
No known previous vascular disease, n (%) 269 (74%) 266 (73%)
History of cardiovascular risk factors, n (%)
Positive family history, n (%) 219 (60%) 220 (60%)
Diagnosed diabetes mellitus, n (%) 49 (13%) 52 (14%)
Dyslipidaemia, n (%) 254 (69%) 263 (72%)
Current smoking, n (%)† 169 (46%) 156 (43%)
Ex-smoker, n (%) 134 (37%) 143 (39%)
Hypertension, n (%) 142 (39%) 130 (36%)
Educational
Fewer than 8 years, n (%) 51 (14%) 47 (13%)
College or university, n (%) 76 (21%) 74 (20%)
Data are n (%) or mean (SD).
*Unless otherwise indicated. Percentages may not sum to 100 because of rounding.
†Smoking status prior to index event.
NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; UAP, unstable angina pectoris.
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Table 2 Number of risk factors on target by treatment group
Baseline 6 months follow-up 12 months follow-up Within group Between group
Nurse group Usual care Nurse group Usual care Nurse group Usual care
Nurse group
Baseline—12
months
Usual care
Baseline—12
months 6 months 12 months
(n=366) (n=367) (n=358) (n=352) (n=359) (n=348) p Value p Value p Value p Value
Body mass index ≤25 kg/m2, n (%) 84 (23%) 105 (29%) 75 (21%) 88 (25%) 77 (21%) 94 (27%) 0.90 0.28 0.21 0.09
Waist circumference men ≤94 cm, women ≤80 cm, n (%) 75 (21%) 99 (27%) 88 (25%) 90 (26%) 82 (23%) 87 (25%) 0.28 0.29 0.86 0.54
Systolic blood pressure ≤140 mm Hg, n (%) 248 (68%) 267 (73%) 256 (72%) 228 (65%) 264 (75%) 211 (61%) 0.02 <0.001 0.05 <0.001
LDL cholesterol ≤2.5 mmol/L, n (%) 247 (68%) 247 (68%) 284 (80%) 241 (69%) 263 (74%) 222 (64%) 0.073 0.11 0.001 0.007
Current smoker*, n (%) 169 (46%) 156 (43%) 77 (22%) 72 (21%) 83 (23%) 85 (25%) <0.001 <0.001 0.78 0.72
Physical activity ≥30 min, ≥5 times per week, n (%) 185 (51%) 185 (50%) 257 (70%) 202 (55%) 239 (66%) 192 (52%) <0.001 0.60 <0.001 <0.001
Alcohol consumption men ≤3 units per day,
women ≤2 units per day, n (%)
347 (95%) 340 (93%) 346 (97%) 336 (95%) 346 (97%) 331 (95%) 0.02 0.004 0.27 0.35
Vegetables ≥200 g per day, n (%) 260 (71%) 243 (66%) 283 (80%) 250 (71%) 286 (80%) 244 (70%) <0.001 0.10 0.02 0.007
Fruit ≥2 pieces per day, n (%) 292 (80%) 307 (84%) 337 (95%) 303 (86%) 332 (93%) 292 (84%) <0.001 0.58 <0.001 <0.001
Other parameters
Triglyceride ≤2.0 mmol/L, n (%) 291 (80%) 291 (80%) 287 (80%) 280 (80%) 277 (78%) 279 (81%) 0.052 0.80 0.93 0.41
HDL cholesterol ≥1.0 mmol/L, n (%) 212 (58%) 207 (57%) 242 (68%) 233 (67%) 243 (69%) 237 (69%) <0.001 <0.001 0.75 0.99
Diastolic blood pressure ≤90 mmHg, n (%) 313 (86%) 319 (87%) 310 (87%) 291 (83%) 297 (84%) 276 (80%) 0.73 0.005 0.14 0.14
Total cholesterol ≤4.5 mmol/L, n (%) 257 (70%) 255 (70%) 280 (78%) 247 (70%) 254 (71%) 251 (73%) 0.93 0.67 0.02 0.74
Data are n (%).
*Number of patients currently smoking, data presented at baseline represents smoking status prior to index event.
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control group in body mass index (BMI) and waist circumference
at 12 months. In the intervention group, an increase was
observed in the number of patients on target at 12-months
follow-up as compared with baseline for systolic blood pressure
(248 (68%) to 264 (75%), p=0.02), physical activity (185 (51%)
to 139 (66%), p<0.001) and vegetable consumption (260 (71%)
to 286 (80%), p<0.001). Conversely, in the control group, risk
factor control deteriorated for systolic blood pressure (267
(73%) to 211 (61%), p<0.001), and remained unchanged for
physical activity (185 (50%) to 192 (52%), p=0.60) and vege-
table consumption (243 (66%) to 244 (70%), p=0.10).
Table 3 presents mean risk factor levels at baseline and
changes at 6 months and 12 months. Weight, BMI and waist cir-
cumference decreased slightly in the intervention group while
remaining unchanged in the control group in 12 months
(weight −0.5 (SD 11.3) vs 0.2 (SD 10.6), p=0.38, BMI −0.2
(SD 4.2) vs 0.03 (SD 3.3), p=0.38, waist circumference
−1.9 cm (SD 13.6) vs 0.2 cm (SD 14.3), p=0.048). Systolic
blood pressure remained unchanged in the intervention group,
while an increase was observed in the control group
(−0.1 mm Hg (SD 17.1) vs 4.2 mm Hg (SD 18.9), p=0.002 for
difference in change).
Figure 2 presents the results of the primary outcome of the
study. The SCORE cardiovascular 10-year mortality risk at base-
line was 5.3 per cent (SD 6.5) in the intervention group and 5.2
per cent (SD 5.5) in the control group (p=0.74). At 6 months
follow-up, SCORE was 4.4 per cent (SD 4.8) in the intervention
group and 5.0 per cent (SD 5.5) in the control group (p=0.12),
corresponding with an absolute reduction of 0.96 per cent
(p<0.001) in the intervention group and an absolute reduction
of 0.19 per cent (p=0.47) in the control group. At 12 months,
SCORE was 4.4 per cent (SD 4.5) in the intervention group and
5.4 per cent (SD 6.2) in the control group (p=0.021), amount-
ing to an absolute reduction of 0.93 per cent relative to baseline
in the intervention group (p<0.001) and an increase of 0.17
per cent (p=0.38) in the control group. The difference in
SCORE between the intervention and control group at
12 months represents a 17.4% reduction in estimated 10-year
cardiovascular mortality.
The results of the FCRS were consistent with those of SCORE.
At baseline, FCRS was 8.5 per cent (SD 5.7) in the intervention
group and 8.1 per cent (SD 5.5) in the control group (p=0.31).
At 6 months, FCRS was 6.9 per cent (SD 5.0) in the intervention
group and 7.4 per cent (SD 5.0) in the control group (p=0.17).
At 12 months, FCRS was 7.0 per cent (SD 5.2) in the
intervention group and 8.0 per cent (SD 5.7) in the control
group (p=0.017). This amounts to an absolute reduction of 1.5
per cent relative to baseline in the intervention group (p<0.001),
and a decrease of 0.05 per cent in the control group (p=0.78).
The difference in FCRS between the intervention group and
control group at 12 months represents a 12.5% reduction in
10-year incidence of coronary mortality and morbidity.
Figure 3 presents the classification of patients according to
the number of risk factors on target. At 12 months, risk factor
control was classified as ‘good’ in 128 (35%) patients in the
intervention group compared with 91 (25%) in the control
group (p=0.003).
Diabetes mellitus was diagnosed in 9 patients in the interven-
tion group compared with 10 patients in the control group
(p=0.99). Based on measurements at follow-up visits, an add-
itional 23 patients in the intervention group and 25 patients in
the control group (p=0.77) qualified for the diagnosis of dia-
betes mellitus. However, treating physicians did not establish a
formal diagnosis of diabetes mellitus in any of these patients.
Table 4 presents the cumulative number of readmissions in
12 months. In total, there were 86 rehospitalisations in the
Table 3 Risk factor change at 6 months and 12 months by treatment group
Value at baseline Change at 6 months Change 12 months 6 months 12 months
Nurse group Usual care Nurse group Usual care Nurse group Usual care
p Value p Value(n=366) (n=367) (n=357) (n=352) (n=359) (n=348)
Weight, kg (SD) 87.2 (15.7) 84.2 (14.3) 0.05 (7.3) 0.3 (7.8) −0.5 (11.3) 0.2 (10.6) 0.62 0.38
Body mass index, kg/m2 (SD) 28.3 (4.4) 27.4 (4.0) 0.03 (2.4) 0.1 (2.5) −0.2 (4.2) 0.03 (3.3) 0.72 0.38
Waist circumference, cm (SD) 100.4 (13.6) 98.6 (13.0) −1.3 (13.2) 0.2 (10.2) −1.9 (13.6) 0.2 (14.3) 0.1 0.048
Systolic blood pressure, mm Hg (SD) 132.7 (21.3) 131.5 (19.8) −0.8 (18.5) 2.7 (18.9) −0.1 (17.1) 4.2 (18.9) 0.014 0.002
Diastolic blood pressure, mm Hg (SD) 79.1 (11.5) 78.6 (11.3) 1.2 (11.4) 2.6 (12.4) 1.9 (11.1) 3.0 (11.4) 0.01 0.20
Total cholesterol, mmol/L (SD) 4.1 (1.0) 4.1 (1.0) −0.1 (1.1) 0.03 (0.9) −0.01 (1.2) 0.02 (1.0) 0.076 0.71
LDL cholesterol, mmol/L (SD) 2.2 (0.9) 2.3 (0.8) −0.1 (1.0) −0.05 (0.9) −0.1 (1.0) 0.03 (0.8) 0.21 0.16
HDL cholesterol, mmol/L (SD) 1.1 (0.3) 1.1 (0.4) 0.1 (0.3) 0.03 (0.5) 0.1 (0.4) 0.02 (0.5) 0.22 0.16
Triglyceride, mmol/L (SD) 1.6 (1.4) 1.5 (0.8) −0.1 (1.1) −0.003 (0.8) −0.01 (0.9) −0.03 (0.8) 0.22 0.71
Data are mean (SD).
Figure 2 SCORE cardiovascular mortality estimation. SCORE at
baseline, 6 months and 12 months. Error bars show 95%-CIs.
ACS=acute coronary syndrome.
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intervention group against 132 in the control group (p=0.023).
This difference was driven by a 67% reduction in readmissions
for non-ACS chest pain (12 admissions vs 36 admissions,
p<0.001). Cardiology emergency room visits occurred less fre-
quently in the intervention group (29 visits vs 51 visits,
p=0.036), while cardiology outpatient visits were slightly more
common (822 visits vs 778 visits, p=0.20). Readmissions for
ACS and elective interventions were comparable in both groups.
Table 5 presents adherence to preventive cardiovascular medi-
cation. The use of antithrombotic agents and lipid lowering
agents was high in both groups. The majority of patients used
blood pressure lowering medication. In the intervention group
diuretics (76 (21%) vs 53(15%), p=0.04) and ACE inhibitors
(201 (57%) vs 160 (46%), p=0.005) were more frequently
prescribed.
DISCUSSION
The main finding of our study is that a practical, hospital-based
nurse-coordinated prevention programme on top of usual care
leads to a reduction in cardiovascular risk. This was observed
using two different risk functions (SCORE and the FCRS) and a
classification of patients according to the number of risk factors
that were on target, including self-reported parameters of life-
style. Moreover, we observed a decrease of in the number of
rehospitalisations in the first 12 months for non-ACS chest pain,
and fewer visits to the cardiac emergency room in patients
attending the nurse-coordinated prevention programme.
The significant improvements in lifestyle parameters that were
observed in the intervention group are not reflected in the
SCORE or Framingham risk functions. The overall impact of
the intervention may therefore be underestimated. The on-target
analysis offers an alternative quantification of benefit, as it
includes parameters on lifestyle. Compared with usual care
alone, the intervention led to a 37% increase in the proportion
of patients that was classified as having ‘good’ control of risk
factors. This risk reduction was achieved against a background
of a high level of usual care, with risk factor levels more favour-
able than those reported in the literature and with excellent
adherence to medication.3 Although our study design included a
specific feature to prevent Hawthorne effects, we cannot
Figure 3 Classification of achievement of risk factor targets per patient (%). Poor control is classified as 0–3 risk factors, fair control is classified
as 4–6 risk factors and good control is classified as 7–9 risk factors on target. Risk factors are smoking, body-mass index <25 kg/m2, waist
circumference for women ≤80 cm, waist circumference for men ≤94 cm, systolic blood pressure <140 mm Hg, LDL cholesterol ≤2.5 mmol/L, physical
activity ≥30 min ≥5 times per week, vegetable consumption ≥200 grams daily, fruit consumption ≥2 pieces daily, alcohol consumption for women
≤2 units per day, alcohol consumption for men ≤3 units per day.
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exclude the possibility that the level of care in the control group
has been positively influenced by participation in the trial. This
could lead to an underestimation of the effects of the interven-
tion. Compared with our control group, a sample of European
patients had lower proportions of patients achieving risk factor
targets, particularly in blood pressure control, total cholesterol,
and use of lipid lowering therapy and blood pressure lowering
agents.3
The multinational EuroAction study showed results similar to
our study.5 However, EuroAction included a complex, multidis-
ciplinary intervention, while our study investigated the impact of
a nursing intervention that is practical, feasible and integrated
into routine clinical care. Consistent with our findings, Murchie
and colleagues reported that nurse led prevention clinics in
general practices in the UK improved medical and lifestyle com-
ponents of secondary prevention.4 Our nurse-coordinated pre-
vention programme took place in a hospital setting and, by
comparison, we included younger patients (58 years vs 66 years)
with a more recent coronary event. The optimal combination of
intervention components, including content, mode of delivery,
frequency and duration remains undetermined according to a
recent meta-analysis.6 A more intensive intervention with more
frequent visits could potentially further improve risk factor
control, especially in complex patients, but this needs to be
assessed in future studies. Our study adds to the existing evidence
that a 6 months nurse-coordinated prevention programme, that
can be easily implemented, leads to an overall decrease in cardio-
vascular risk that is sustained at 1 year after an ACS.
The observed difference in hospital readmissions for non-ACS
chest pain and visits to the cardiac emergency ward was not
anticipated. It may reflect the effectiveness of the counselling
component of the nurse programme in preventing unnecessary
hospital readmissions and emergency-room visits. However, this
was a non-prespecified secondary outcome and this observation
requires independent confirmation.
Ideally, the impact of a preventive intervention would be
quantified at the level of individual mortality risk. For secondary
prevention, individual predictors have been described.14 15
However, these observations are based on short-term outcomes
and, more importantly, no risk function is currently available
that integrates all predictors into an overall estimation of cardio-
vascular mortality risk. For lack of a validated risk function in
secondary prevention, we selected the SCORE function for
10-year cardiovascular risk as the primary outcome in our sec-
ondary prevention trial. A recently published, comparable trial
has similarly used a primary prevention risk score as the main
outcome measure to quantify the effect of a secondary preven-
tion programme.16 Although the absolute estimates of the
SCORE function are inaccurate in secondary prevention, the dif-
ference in SCORE between the two groups provides an estimate
of the relative overall impact of a risk factor intervention. Our
analysis suggests a 17.4% relative risk reduction compared with
usual care alone.
Table 4 Hospital readmissions, cardiac emergency room visits and
cardiology outpatient visits
Total
(n=710)
Nurse
group
(n=361)
Usual care
(n=349)
p
Value
Total number of
readmissions
218 86 (39%) 132 (61%) 0.023
Readmissions for ACS 38 17 (45%) 21 (55%) 0.58
STEMI 12 4 (33%) 8 (67%) 0.35
NSTEMI 8 4 (50%) 4 (50%) 0.99
UAP 18 9 (50%) 9 (50%) 0.98
Other CVD
readmissions
82 21 (26%) 61 (74%) <0.001
Chest pain no ACS 48 12 (25%) 36 (75%) 0.001
Atrial fibrillation 9 2 (22%) 7 (78%) 0.09
Congestive HF 6 0 (0%) 6 (100%) 0.034
CVA 3 1 (33%) 2 (67%) 0.57
Others 16 6 (38%) 10 (63%) 0.40
Interventions 29 12 (41%) 17 (59%) 0.41
CAG 6 2 (33%) 4 (67%) 0.42
PCI 21 9 (43%) 12 (57%) 0.54
CABG 2 1 (50%) 1 (50%) 0.99
Elective interventions 98 48 (49%) 50 (51%) 0.68
CAG 61 32 (52%) 29 (48%) 0.67
PCI 26 12 (46%) 14 (54%) 0.74
CABG 11 4 (36%) 7 (64%) 0.37
Cardiac emergency room
visits
80 29 (36%) 51 (64%) 0.036
Outpatient cardiology
visits
1600 822 (51%) 778 (49%) 0.20
Data are numbers of admissions, interventions or visits (%) as applicable.
ACS, acute coronary syndrome; CABG, coronary artery bypass surgery; CAG, coronary
angiography; CVA, cerebrovascular accident; CVD, cardiovascular disease; HF, heart
failure; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous
coronary interventions; STEMI, ST segment elevation myocardial infarction; UAP,
unstable angina pectoris.
Table 5 Secondary cardiovascular preventive medication by treatment group
Baseline 6 months follow-up 12 months follow-up 6 months 12 months
Nurse group Usual care Nurse group Usual care Nurse group Usual care
p Value p Value(n=366) (n=367) (n=358) (n=352) (n=355) (n=348)
Any antithrombotic agent*, n (%) 363 (99%) 363 (99%) 354 (99%) 354 (99%) 348 (98%) 342 (98%) 0.99 0.99
Any lipid lowering agent†, n (%) 350 (96%) 352 (96%) 345 (96%) 337 (96%) 331 (93%) 328 (94%) 0.70 0.64
β Blockers, n (%) 328 (90%) 326 (89%) 296 (83%) 285 (81%) 270 (76%) 272 (78%) 0.56 0.53
Calcium channel blocker, n (%) 65 (18%) 65 (18%) 82 (23%) 58 (17%) 77 (22%) 65 (19%) 0.04 0.35
Diuretics, n (%) 52 (14%) 52 (15%) 74 (21%) 53 (15%) 76 (21%) 53 (15%) 0.06 0.04
ACE inhibitors, n (%) 200 (55%) 175 (48%) 209 (58%) 162 (46%) 201 (57%) 160 (46%) 0.001 0.005
Angiotensin II receptor blockers, n (%) 36 (10%) 32 (9%) 56 (16%) 49 (14%) 58 (16%) 55 (16%) 0.53 0.92
α Blockers, n (%) 0 (0%) 3 (1%) 0 (0%) 4 (1%) 0 (0%) 4 (1%) 0.06 0.06
Data are n (%).
*Antithrombotic agents are aspirine, clopidogrel, dipyridamol or any oral anticoagulant.
†Lipid lowering agents are statins or non-statin lipid lowering agents.
1428 Jorstad HT, et al. Heart 2013;99:1421–1430. doi:10.1136/heartjnl-2013-303989
Secondary prevention of coronary disease
 group.bmj.com on November 28, 2013 - Published by heart.bmj.comDownloaded from 
Although these results are encouraging, there is room for
improvement. Weight loss was insufficient in both groups, in
spite of an increase in self-reported adequate physical exercise
and improved food choices. However, the intervention group
had a mean decrease in waist circumference of 1.9 cm, whereas
the control group had an increase of 0.2 cm, potentially reflect-
ing the effects of lifestyle changes. The large number of smokers
who quit in both groups could potentially have been a factor
limiting weight loss. The slightly higher weight in the interven-
tion group at follow-up may be explained by the higher weight
at baseline and the slightly higher proportion of patients who
quit smoking. Given the encouraging results in the pharmaco-
logical components of the programme, the most important
opportunities for further improvement are found in lifestyle
parameters. In particular, there is an unmet need for strategies
for weight loss and smoking cessation.
Attendance to the nurse-coordinated prevention programme
for the four visits in the first 6 months of the study was excel-
lent. Patients were willing to visit the clinic and to complete the
programme. Locally selected registered nurses with limited add-
itional training were able to execute the programme and were
comfortable with the protocol. Consequently, we believe the
programme is feasible and practical and can be implemented
into routine care. In addition, since the risk factors for athero-
sclerotic complications in other arterial territories are largely the
same as in CAD, a similar approach may be considered for
patients with cerebral and peripheral arterial disease.
Limitations
Some aspects of our trial warrant consideration. We excluded
patients unable to attend the nurse clinics, and patients with a
limited life expectancy. Potentially, this group of patients is
older, sicker and less mobile than our study population. Possibly,
patients with decreased mobility could benefit from other
approaches, such as a telephonic nurse-coordinated prevention
programme. However, this was not part of our investigation.
Our study population consisted of a slightly lower proportion
of women as compared with other national and international
surveys. In the European Action on Secondary and Primary
Prevention by Intervention to Reduce Events (EUROASPIRE) III
survey, performed in 22 countries in Europe (including the
Netherlands), 27% of participants were women.3 In the
Netherlands, 33% of all hospital admissions (88 765) for ischae-
mic heart disease in 2011 were in women.17
We excluded patients aged ≥80 years at the index event.
Excluding these individuals lead to a slightly lower mean age
(58 years) of our study population as compared with the mean
age in other European cohorts of patients with ACS (eg,
62 years in EUROASPIRE III).3 The effects of a Nurse-coordi-
nated prevention programme (NCPP) in patients >80 years of
age cannot be derived from our findings.
Our data on physical activity were self-reported. While we
collected data on the duration and intensity of the physical
activity, we did not assess cardiopulmonary fitness or exercise
capacity. Potentially, a relevant increase in exercise capacity
could also have occurred in patients who exercised less than
150 min per week.
CONCLUSION
The RESPONSE trial demonstrates that a nurse-coordinated
hospital-based prevention programme with up to four out-
patient clinic visits in addition to usual care results in sustained
lowering of cardiovascular risk in patients with coronary
disease. The programme was well attended, practical and can be
readily implemented into daily practice. In addition, our data
suggest that the counselling component of the programme pre-
vents unnecessary hospital readmissions.
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